Who are Neulasta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Neupogen, Neulasta® (pegfilgrastim), LENOGRASTIM (GRANOGYTE 34), PEG-G-CSF, Pegfilgrastim-Cbqv, QL0605(PEG-rhG-CSF).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nyvepria.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Neulasta — Competitive Intelligence Brief

Neulasta (Pegfilgrastim-Apgf) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Colony-stimulating factor. Area: Hematology.

marketed Colony-stimulating factor G-CSF receptor on hematopoietic cells Hematology Live · refreshed every 30 min

Target snapshot

Neulasta (Pegfilgrastim-Apgf) — Amgen. Colony-stimulating factor binding hematopoietic cell surface receptors to stimulate proliferation and differentiation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Neulasta TARGET	Pegfilgrastim-Apgf	Amgen	marketed	Colony-stimulating factor	G-CSF receptor on hematopoietic cells	2002-01-01
Neupogen	Filgrastim-Aafi	Amgen	marketed	Colony-stimulating factor (CSF); leukocyte growth factor	G-CSF receptor (granulocyte colony-stimulating factor receptor)	1991-01-01
Neulasta® (pegfilgrastim)	Neulasta® (pegfilgrastim)	Amgen	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
LENOGRASTIM (GRANOGYTE 34)	LENOGRASTIM (GRANOGYTE 34)	Sanofi	marketed	Granulocyte colony-stimulating factor (G-CSF)	G-CSF receptor (GCSFR)
PEG-G-CSF	PEG-G-CSF	Sanofi	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
Pegfilgrastim-Cbqv	Pegfilgrastim-Cbqv	Coherus Oncology, Inc.	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
QL0605(PEG-rhG-CSF)	QL0605(PEG-rhG-CSF)	Qilu Pharmaceutical Co., Ltd.	marketed	Pegylated G-CSF (granulocyte colony-stimulating factor)	G-CSF receptor (GCSFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Colony-stimulating factor class)

Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Neulasta — Competitive Intelligence Brief. https://druglandscape.com/ci/nyvepria. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab